|
|
C F S
- Information International 37 kDa RNase
L
|
|
|
The importance of the Rnase pathway
Antiviral pathway deregulation
of CFS induces NO production in immune cells that precludes a resolution of
the Inflammatory response, fremont.etal06.txt,
fremont.etal06.pdf. Intracellular immune
dysfunction in ME/CFS: state of the art and therapeutic implications, nijs.fremont07.txt. 37 kDa protein - characterization
The ongoing process of
characterizing the 37 kDa protein by sophisticated biochemical methods, Shetzline & Suhadolnik, 2001, Shetzline & Suhadolnik, 2001 (pdf). More basic
biochemistry by the Belgian team on the RNase-L split products, Englebienne et al., 2001., and on the
characterization,
Shetzline et al., 2002. Further evidence for the 37 kDa being a
truncated form of the native 2-5A dependent ribonuclease L (RNase L),
generated by an increased proteolytic activity in CFS cell extracts, Demettre et al., 2002. A 2003-review, englebienne03.txt and an editorial about CFS and Rnase L, editorial.jcfs03.txt. fremont.etal05.txt,
fremont.etal05.pdf : 2',5'-Oligoadenylate
size is critical to protect RNase L against proteolytic cleavage in CFS. Apoptosis and RNase L activation
Downregulation of the RNase L enzyme
cascade, possibly caused by RNA segments, resulting in a defect in the normal
apoptosis (cell suicide) process, is found both in CFS and MS cells, Englebienne et al., 2001. 37 kDa protein and Ampligen
There are results indicating
that patients who have the 37 kDa RNaseL, besides having 'a CFS marker', also
benefit the most from Ampligen treatment, De Meirleir et al., 2000, De Meirleir et al., 2000 (full paper). RNaseL and Mycoplasma
Two papers were presented in RNaseL and a Disease Model
A disease model for CFS
involving RnaseL,
Mc Gregor et al., 2001. Contrary to this view, Dr W. Behan states
that CFS is not a simple viral disease, and tests for acute activation of the
antiviral pathway leads nowhere,
Behan et al., 2001. Comparing physical performance and test results
for RNase activation, found no simple correlation, Snell et al., 2002. Japanese researchers have
studied these complicated enzymatic processes and found correlation between
Coxiella virus infection in CFS and the enzyme, 2`, 5`-oligoadenylate
synthetase, ikuta.etal03.pdf. An overview
of the evidence addressing the impairments of the 2'-5' oligoadenylate (2-5
A) synthetase/RNase L pathway in CFS patients, nijs.demeirleir05.txt. Rnase L - G-Actin-splitproduct - a Serum marker for CFS ?
The Belgian research team
introduced a possible serum marker for increased RNase activity, the split
product of G-actin, Roelens et al., 2001. In 2002 these researchers presented a book
on RNase and CFS,
book, De Meirleir, 2002, and a commercial test for CFS, the
detection of G-actin fragments in serum, based on the above findings, test, G actin, 2002. Patents relating to the above
findings by the Belgian researchers,
patents, CFS, 2002. A list of antibiotics to be included in
the treatment regime has also been patented, antibiotics.list.deMeileir03.txt. A study from the US disproved
specific RNAse findings in CFS,
Vernon et al., 2002 (short), Vernon et al., 2002. A recent paper found the RNaseL test to be able to
distinguish CFS from controls,
Tiev et al., 2003 (short) Tiev
et al., 2003 (paper) Tiev
et al., 2003 (pdf). Examination of the relationship between clinical and
functional characteristics, immune abnormalities and status of the RNase L
pathway in CFS compared with healthy control and depression control
populations, supported the cytokine/immune activation model in a
well-characterized CFS patient group, suhadolnik.etal04.txt, suhadolnik.etal04.pdf. Micro RNA - a new player on the Scene
New information on this
interesting topic, news.microrna05.txt. |
|
Index Welcome CFS
case def. Prevalence Prognosis Brain
Inflam Post-Polio Hypotheses This website is 100% non-commercial and independent
of associations and public authorities. |
|